Obesity Partnerships Zealand Pharma's obesity programs are backed by Roche and Boehringer Ingelheim, signaling strong co development and potential co commercial opportunities. This presents a sales opening for CRO/CDMO services, data analytics, pharmacovigilance, regulatory support, and manufacturing partnerships to accelerate obesity drug development and scale production.

Competitive Landscape Facing competition from Novo Nordisk and Eli Lilly in weight loss therapies, there is a clear need for market access strategy, health economics and outcomes research, and payer engagement. Opportunities exist to offer HEOR studies, payer dossiers, launch readiness consulting, and digital patient engagement solutions.

Data Tech Enablement Zealand's tech stack includes SAS, OneTrust, Microsoft Fabric, and Dynamics, indicating readiness for advanced analytics and governance. There is room to provide data platform modernization, analytics outsourcing, safety data management, and regulatory reporting services to accelerate R&D and commercialization.

Global Ops Support With a Copenhagen base and a US presence, Zealand can benefit from global clinical operations, cross border regulatory submissions, and scalable manufacturing partnerships for peptide medicines to support international trials and market access.

IR and Fundraising Recent leadership changes and an active investor relations function suggest emphasis on investor communications and market messaging. Services in market intelligence, financial communications, and targeted investor outreach could help optimize fundraising and stakeholder engagement.